X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PC14586 (rezatapopt) first-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation. It is being evaluated for the treatment of P53 Y220C-positive solid tumors.
Lead Product(s): Rezatapopt,Pembrolizumab
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Under the agreement, PMV Pharma will sponsor the trial and Merck will supply KEYTRUDA. PMV Pharma will evaluate PC14586 in combination with KEYTRUDA as a separate arm of the company’s ongoing Phase 1/2 PYNNACLE trial in patients with advanced solid tumors.
Lead Product(s): PC14586,Pembrolizumab
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 18, 2022
Details:
PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.
Lead Product(s): PC14586
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors. The preliminary clinical pharmacokinetics data showed dose proportional increases in Cmax and AUC.
Lead Product(s): PC14586
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a p53 Y220C mutation.
Lead Product(s): PC14586
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The Phase 1/2 study will evaluate PC14586 to treat advanced solid tumors with a p53 Y220C mutation. PC14586 is novel p53 reactivator that selectively binds to the crevice created by the p53 Y220C mutant protein, hence, restoring the normal p53 protein structure and function.
Lead Product(s): PC14586
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
PC14586 is a first-in-class small molecule designed to structurally correct the p53 Y220C mutant protein. There are currently no FDA-approved medicines that target the p53 Y220C mutation.
Lead Product(s): PC14586
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The company's lead candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation while sparing wild-type p53.
Lead Product(s): PC14586
Therapeutic Area: Oncology Product Name: PC14586
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 21, 2020
Details:
The proceeds from the financing provides PMV Pharma with the resources to expand its pipeline and to potentially advance multiple p53 therapies into the clinic.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avoro Capital
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
